AAV-8 gene therapy in canine diabetes mellitus; a potential future treatment?

Foale, Rob; Recino, Asha; Wållberg, Maja; Gan, S. Ian; Ko, Lee; Nathwani, Amit C.; Lever, Andrew M. L.; Calne, Sir Roy

doi:10.22233/9781910443439.61.5

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the vector was systemically injected and specifically expressed in the liver of streptozotocin (STZ)-induced diabetic mice [ 5 ] and non-obese diabetic (NOD) mice [ 6 ], we observed a decrease in the hyperglycemia and restoration of weight in the treated mice. We have also reported preliminary results of similar study in a naturally occurring diabetic dog [ 8 ].…”

Section: Introductionmentioning

confidence: 96%

Modification of a Constitutive to Glucose-Responsive Liver-Specific Promoter Resulted in Increased Efficacy of Adeno-Associated Virus Serotype 8-Insulin Gene Therapy of Diabetic Mice

Sia

Calne

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

We have previously used a hepatotropic adeno-associated viral (AAV) vector with a modified human insulin gene to treat diabetic mice. The HLP (hybrid liver-specific promoter) used was constitutively active and non-responsive to glucose. In this study, we examined the effects of addition of glucose responsive elements (R3G) and incorporation of a 3′ albumin enhancer (3′iALB) on insulin expression. In comparison with the original promoter, glucose responsiveness was only observed in the modified promoters in vitro with a 36 h lag time before the peak expression. A 50% decrease in the number of viral particles at 5 × 109 vector genome (vg)/mouse was required by AAV8-R3GHLP-hINSco to reduce the blood sugar level to near normoglycemia when compared to the original AAV8-HLP-hINSco that needed 1 × 1010 vg/mouse. The further inclusion of an 860 base-pairs 3′iALB enhancer component in the 3′ untranslated region increased the in vitro gene expression significantly but this increase was not observed when the packaged virus was systemically injected in vivo. The addition of R3G to the HLP promoter in the AAV8-human insulin vector increased the insulin expression and secretion, thereby lowering the required dosage for basal insulin treatment. This in turn reduces the risk of liver toxicity and cost of vector production.

show abstract

Section: Introductionmentioning

confidence: 96%